Search Result

Results for "

αSMA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amine N-methyltransferase (1) Angiotensin Receptor (2) Apoptosis (3) Autophagy (1) Bcr-Abl (1) c-Myc (1) Collagen (1) CXCR (1) Cytochrome P450 (1) Epigenetic Reader Domain (1) ERK (2) FGFR (1) FLT3 (1) FXR (1) Galectin (1) Glutaminase (1) Hedgehog (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) JAK (1) JNK (1) MMP (1) mTOR (1) NF-κB (1) P2Y Receptor (1) p38 MAPK (1) PDGFR (1) Phosphatase (1) Phosphodiesterase (PDE) (3) Pim (1) PPAR (1) Sirtuin (1) TGF-beta/Smad (5) TGF-β Receptor (4) TRP Channel (1) VD/VDR (1) VEGFR (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (6) Endocrinology (1) Inflammation/Immunology (22) Metabolic Disease (3) Neurological Disease (1)

By Targets:

5-HT Receptor (1)

Amine N-methyltransferase (1)

Angiotensin Receptor (2)

Apoptosis (3)

Autophagy (1)

Bcr-Abl (1)

c-Myc (1)

Collagen (1)

CXCR (1)

Cytochrome P450 (1)

Epigenetic Reader Domain (1)

ERK (2)

FGFR (1)

FLT3 (1)

FXR (1)

Galectin (1)

Glutaminase (1)

Hedgehog (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Interleukin Related (1)

JAK (1)

JNK (1)

MMP (1)

mTOR (1)

NF-κB (1)

P2Y Receptor (1)

p38 MAPK (1)

PDGFR (1)

Phosphatase (1)

Phosphodiesterase (PDE) (3)

Pim (1)

PPAR (1)

Sirtuin (1)

TGF-beta/Smad (5)

TGF-β Receptor (4)

TRP Channel (1)

VD/VDR (1)

VEGFR (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (6)

Endocrinology (1)

Inflammation/Immunology (22)

Metabolic Disease (3)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151932

FXR agonist 3	FXR	Inflammation/Immunology
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, *α-SMA* and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .

HY-133897

(Rac)-Indoximod 1 Publications Verification 1-Methyl-DL-tryptophan; (Rac)-NLG-8189	Indoleamine 2,3-Dioxygenase (IDO) Apoptosis	Inflammation/Immunology Cancer
(Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (IDO) inhibitor. Co-treatment with IFN-γ and (Rac)-Indoximod markedly reduces the activity of human cardiac myofibroblasts (hCMs) expressing α-SMA and induces apoptosis through up-regulating the IRF-1, Fas, and FasL genes .

HY-143237

ATX inhibitor 11	Phosphodiesterase (PDE)	Others
ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research .

HY-N12703

N-Acetyldopamine dimmers A	Others	Inflammation/Immunology
N-Acetyldopamine dimmers A (Compound (+)-2) can be isolated from the cast-off shell of the cicada of Cryptotympana sp. N-Acetyldopamine dimmers A increases collagen and α-SMA expression .

HY-170578

SIRT2-IN-17	Sirtuin	Neurological Disease
SIRT2-IN-17 (compound Z18) is a potent SIRT2 inhibitor. SIRT2-IN-17 reduces the expression of *α-SMA* and p-Smad2/3 .

HY-162929

TP-DEA2	TGF-β Receptor	Inflammation/Immunology
TP-DEA2, a predictable-release Triptolide (HY-32735) prodrug, block Bleomycin-induced pulmonary fibrosis and inflammation. TP-DEA2 significantly inhibits α-SMA production .

HY-P11112

PTD-DBM	β-catenin Wnt	Inflammation/Immunology
PTD-DBM is a competitive peptide that blocks the CXXC5-Dvl interaction and induces the expression of β-catenin, α-SMA, and type I collagen. PTD-DBM has skin wound healing activity .

HY-116307

2-Thio-UTP	P2Y Receptor	Cardiovascular Disease
2-Thio-UTP is a selective P2Y₂ inhibitor with an EC₅₀ value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .

HY-172105

Anti-NASH agent 2	PPAR	Metabolic Disease Inflammation/Immunology
Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models .

HY-114366

BC-1485	CXCR	Others
BC-1485 is a small molecule inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1). BC-1485 protects PIAS4 from ubiquitin-mediated degradation. BC-1485 decreases *α-SMA, BAL* and CXCL1. BC-1485 ameliorates fibrotic lung injury in murine models .

HY-100446

NTU281	Glutaminase Apoptosis	Metabolic Disease Inflammation/Immunology
NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes .

HY-151427

TGFβ1-IN-1 2 Publications Verification	TGF-β Receptor	Inflammation/Immunology
TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies .

HY-178328

VDR agonist 4	VD/VDR Collagen TGF-beta/Smad MMP JAK	Metabolic Disease Inflammation/Immunology Endocrinology
VDR agonist 4 is an orally active potent VDR agonist. VDR agonist 4 exerts VDR-dependent antifibrotic activity by regulating multiple fibrosis-related genes to suppress α-SMA and collagen I production, thereby inhibiting hepatic stellate cell (HSC) activation. VDR agonist 4 improves CCl₄ (HY-RS16594)-induced hepatic fibrosis in mice. VDR agonist 4 can be used for liver fibrosis research .

HY-162147

Nur77 modulator 3	mTOR Autophagy	Inflammation/Immunology
Nur77 modulator 3 (9e) can bind to Nur77 and inhibit TGF-β1-induced α-SMA and COLA1 expression in a Nur77-dependent manner. Nur77 modulator 3 induces Nur77 expression and enhances autophagic flux by inhibiting the mTORC1 signaling pathway in vitro and in vivo. Nur77 modulator 3 blocks the progression of hepatic fibrosis .

HY-170227

Autotaxin-IN-7	Phosphodiesterase (PDE) TGF-β Receptor	Inflammation/Immunology
Autotaxin-IN-7 (45), a pyridine-2-carboxylic derivative, demonstrates subnanomolar ATX inhibition (IC₅₀ = 0.086 nM), with a favorable heart safety profile (hERG > 30 μM) and minimal fibroblast toxicity. Autotaxin-IN-7 (45) suppresses the TGF-β/Smad signaling pathway, downregulating α-smooth muscle actin (α-SMA) and extracellular matrix components (ECM). Autotaxin-IN-7 (45) is used in the research for pulmonary fibrosis .

HY-117485

CBR-096-4	Hedgehog	Inflammation/Immunology
CBR-096-4 is a derivative of Itraconazole (HY-17514). CBR-096-4 is an orally active antifibrotic agent with no CYP3A4 inhibitory activity. CBR-096-4 inhibits the formation of matrix-secreting activated myofibroblasts (MFBs) from multiple tissue types. CBR-096-4 inhibits Hedgehog reporter activity (GLI-LUC), VEGF-dependent growth, and αSMA-LUC reporter activity. CBR-096-4 can be used for research of fibrosis .

HY-146434

TGFβ-IN-2 1 Publications Verification	TGF-beta/Smad	Inflammation/Immunology
TGFβ-IN-2 is an orally active TGF-β inhibitor. TGFβ-IN-2 suppresses the TGF-β-induced protein expression of COL1A1, α-SMA, and p-Smad3 in vitro. TGFβ-IN-2 demonstrates excellent anti-fibrotic efficacy in Bleomycin (HY-108345)-induced pulmonary fibrosis model. TGFβ-IN-2 can be used for the study of pulmonary fibrosis .

HY-175603

NCGC00685960	Amine N-methyltransferase	Cancer
NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC₅₀ < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research .

HY-175277

PIM1-IN-8	Pim NF-κB Interleukin Related	Inflammation/Immunology
PIM1-IN-8 is a PIM1/p65 pathway inhibitor. PIM1-IN-8 suppresses the expression of α-SMA and collagen I in activated fibroblasts and blocks TGF-β induced migration. PIM1-IN-8 alleviates pulmonary fibrosis in a Bleomycin (BLM) (HY-17565A)-induced pulmonary fibrosis mice model. PIM1-IN-8 can be used for the study of idiopathic pulmonary fibrosis (IPF) .

HY-170839

TRPV1-IN-3	TRP Channel	Inflammation/Immunology
TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and *α-SMA* by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC₅₀=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345) .

HY-162902

ALK5-IN-82	TGF-β Receptor	Cardiovascular Disease
ALK5-IN-82 is a potent and selective inhibitor against activin receptor-like kinase 5 (ALK5) with an IC₅₀ value of 9.1 nM. ALK5-IN-82 inhibits the protein expression of α-smooth muscle actin (α-SMA), collagen I and tissue inhibitor of metalloproteinase 1 (TIMP-1)/matrix metalloproteinase 13 (MMP-13) in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is promising for research of cardiac fibrosis .

HY-176737

TGF-β1/Smad-IN-1	TGF-beta/Smad	Inflammation/Immunology
TGF-β1/Smad-IN-1 (compound C9) is a potent TGF-β1/Smad inhibitor. TGF-β1/Smad-IN-1 inhibits the expression of fibrosis markers (α-SMA and COL1A1) induced by TGF-β1. TGF-β1/Smad-IN-1 shows antifibrotic effects. TGF-β1/Smad-IN-1 has the potential for the research of hepatic fibrosis .

HY-173235

Galectin-3-IN-6	Galectin	Cardiovascular Disease Inflammation/Immunology Cancer
Galectin-3-IN-6 (Compound 12) is an orally active inhibitor of galectin-3 (Gal-3), with an IC₅₀ value of 12 nM and a K_d value of 13 nM for Gal-3. In a mouse model of acute liver injury and fibrosis induced by CCl4, Galectin-3-IN-6 can significantly reduce the levels of fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, showing significant anti-fibrotic activity. Galectin-3-IN-6 can be used in the research of fibrotic diseases, cancer, and cardiovascular diseases .

HY-P11223

CMF9	TGF-beta/Smad	Inflammation/Immunology
CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction. CMF9 effectively blocks the formation of the heterodimeric complex of SMAD2 and SMAD4 by inhibiting the phosphorylation of SMAD2. CMF9 has no effect on the phosphorylation of SMAD3 or SMAD1/5/8. CMF9 downregulates the expression of fibrotic markers *α-SMA* and COL1A1. CMF9 exhibits potent anti-fibrotic effects in mouse models by promoting the degradation of pathological extracellular matrix (ECM) and inhibiting inflammation. CMF9 can be used for the study of liver fibrosis .

HY-P3136A

TRV055 hydrochloride TRV120055 hydrochloride	Angiotensin Receptor	Cardiovascular Disease
TRV055 (TRV120055) (hydrochloride) is a G protein-biased agonist of angiotensin II type 1 receptors (AT1Rs). TRV120055 induces fibroblast proliferation, overexpression of collagen I and α-SMA, and stress fibre formation in human cardiac fibroblasts. TRV055 activates AT1 receptor/Gαq-mediated signaling pathways, upregulates TGF-β1 and p-ERK1/2. TRV055 induces collagen secretion in adult rat myofibroblasts at a level comparable to Ang II. TRV055 can be used to study the role of G protein-biased signaling of AT1Rs in regulating fibrotic responses ^[1]

HY-162888

WQ-C-401	PDGFR ERK	Cardiovascular Disease
WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC₅₀ values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing *α-SMA* expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .

HY-P3136

TRV055 TRV120055	Angiotensin Receptor ERK	Cardiovascular Disease
TRV055 (TRV120055) is a G protein-biased agonist of angiotensin II type 1 receptors (AT1Rs). TRV120055 induces fibroblast proliferation, overexpression of collagen I and α-SMA, and stress fibre formation in human cardiac fibroblasts. TRV055 activates AT1 receptor/Gαq-mediated signaling pathways, upregulates TGF-β1 and p-ERK1/2. TRV055 induces collagen secretion in adult rat myofibroblasts at a level comparable to Ang II. TRV055 can be used to study the role of G protein-biased signaling of AT1Rs in regulating fibrotic responses ^[1]

HY-169177

JNK-1-IN-4	JNK	Inflammation/Immunology
JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC₅₀s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .

HY-172258

5-HT2B antagonist-2	5-HT Receptor	Cancer
5-HT2B antagonist-2 (Compound 19c) is a 5HT_2B receptor antagonist with an IC₅₀ of 1.09 nM. 5-HT2B antagonist-2 can downregulate the expression of fibrosis-related genes α-SMA, Timp1, Col1a1, and Col3a1, and significantly reduce the deposition of fibrosis, thereby reducing the fibrotic area and inhibiting the fibrotic process in CCl4-induced liver fibrosis mouse models. 5-HT2B antagonist-2 can be used in the study of immune inflammatory-related diseases, particularly in the research of pulmonary fibrosis diseases .

HY-175033

BRD4-IN-11	Epigenetic Reader Domain Phosphatase c-Myc Apoptosis	Inflammation/Immunology
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC₅₀ = 26.35 nM (BD1), IC₅₀ = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .

HY-179042

TGF-β/Smad-IN-3	TGF-beta/Smad p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
TGF-β/Smad-IN-3 (Compound 4w) is an effective TGF-β/Smad inhibitor. TGF-β/Smad-IN-3 exerts anti-pulmonary fibrosis activity by simultaneously inhibiting the TGF-β/Smad and MAPK signaling pathways. TGF-β/Smad-IN-3 significantly inhibits collagen deposition induced by TGF-β1, with its IC₅₀ value being 3.21 μM. TGF-β/Smad-IN-3 has an IC₅₀ of 46.77 nM for the autocrine motility factor (ATX). TGF-β/Smad-IN-3 significantly reduces the expression levels of α-SMA, COL1A1 and FN in TGF-β1-induced CCC-HPF-1 cells, and effectively inhibited TGF-β1-induced cell migration. TGF-β/Smad-IN-3 can be used for the study of pulmonary fibrosis .

HY-170846

FGFRs-IN-1	FGFR VEGFR Bcr-Abl FLT3 Cytochrome P450	Inflammation/Immunology
FGFRs-IN-1 (Compound A16) is the orally active inhibitor for FGFR, that inhibits FGFR1/2/3/4 with IC₅₀s of 2.3, 7, 11, and 163 nM, respectively. FGFRs-IN-1 also inhibits VEGFR1/2/3, Abl, and Flt3 with IC₅₀s of 61, 176, 112, 26, and 353 nM, respectively. FGFRs-IN-1 exhibits weak inhibitory efficacy against CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and inhibits epithelial-mesenchymal transition (EMT) in TGF-β1 stimulated A549 cell. FGFRs-IN-1 exhibits anti-inflammatory activity in Bleomycin (HY-17565)-induced mouse pulmonary fibrosis model and CCl₄ (HY-Y0298)-induced mouse liver fibrosis model .

Cat. No.	Product Name	Target	Research Area